The 10 most recent market catalysts affecting $PRME, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 12, 2026
Corporate Catalyst
Neutral
Impact 75
Prime Medicine Reports Third Quarter 2026 Financial Results
Prime Medicine reported its third-quarter 2026 financial results, but the more significant disclosure is the initiation of a Phase 1/2 clinical trial for PM577a, its lead candidate…
Nov 11, 2026
Corporate Catalyst
Neutral
Impact 65
Prime Medicine Announces Pricing of Public Offering of Common Stock
Prime Medicine, Inc. has priced a public offering of common stock to raise $125 million. This capital infusion is crucial for a biotechnology company like Prime Medicine, which typ…
Nov 10, 2026
Corporate Catalyst
Neutral
Impact 75
Prime Medicine Announces Proposed $125 Million Public Offering of Common Stock
Prime Medicine announced a proposed underwritten public offering of $125 million of its common stock, with an additional $18.75 million option for underwriters. This move is a capi…
Sep 25, 2026
Corporate Catalyst
Bullish
Impact 75
Prime Medicine Gets FDA Green Light for Gene Editing Study
Prime Medicine announced FDA clearance for its IND application for PM647, an investigational gene-editing therapy for Alpha-1 Antitrypsin Deficiency (AATD). This is a crucial miles…
Sep 24, 2026
Corporate Catalyst
Bullish
Impact 85
Prime Medicine shares are trading higher after the company announced the FDA clearance of its Investigational New Drug application for PM647 in Alpha-1 antitrypsin deficiency.
The FDA Investigational New Drug (IND) clearance for PM647 is a major positive catalyst for Prime Medicine, as it allows the company to proceed with human clinical trials. This sig…
Sep 24, 2026
Corporate Catalyst
Bullish
Impact 75
FDA Clears Prime Medicine’s IND Application For PM647, Investigational In Vivo Prime Editor For Alpha-1 Antitrypsin Deficiency
Prime Medicine announced that the FDA has cleared its Investigational New Drug (IND) application for PM647, an in vivo Prime Editor targeting Alpha-1 Antitrypsin Deficiency (AATD).…
Aug 19, 2026
Corporate Catalyst
Bullish
Impact 75
Prime Medicine shares are trading higher after BMO Capital initiated coverage on the stock with an Outperform rating and announced a $9 price target.
The initiation of coverage with an 'Outperform' rating and a specific price target from a reputable firm like BMO Capital is a strong positive catalyst for Prime Medicine. This act…
Aug 19, 2026
Corporate Catalyst
Neutral
Impact 65
BMO Capital Initiates Coverage On Prime Medicine with Outperform Rating, Announces Price Target of $9
BMO Capital's initiation of coverage on Prime Medicine with an Outperform rating and a $9 price target is a positive development for the company. Analyst coverage, especially from …
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 75
Prime Medicine Q2 EPS $(0.24) Beats $(0.26) Estimate, Sales $1.154M Miss $1.295M Estimate
Prime Medicine (PRME) released its Q2 earnings, reporting a smaller loss per share than anticipated by analysts, which is a positive sign for cost management and operational effici…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.